Stevanato Group S.p.a. · NYSE:STVN
Stevanato — Q3 2026 Earnings Presentation
22 slides from Stevanato's earnings presentation, Nov 3, 2026
Slide 1: Stevanato Group Q3 2026 Financial Results
Stevanato Group Q3 2026 Financial Results November 3, 2026 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) a
Slide 3: Earnings Call Participants
Stevanato Group Q3 2026 Financial Results Earnings Call Marco Dal Lago CFO Lisa Miles CCO & IR Franco Stevanato Chairman & CEO Q3 2026 Financial Results
Slide 4: Franco Stevanato, Chairman & CEO
Franco Stevanato Chairman & CEO Q3 2026 Financial Results
Slide 5: Q3 2026: 8% Topline Growth and Expanded Adjusted EBITDA Margin
Q3 2026: 8% Topline Growth and Expanded Adjusted EBITDA Margin Revenue Growth & Magin Expansion driven by BDS In Q3 2026, revenue grew 8%, driven by 11% organic* growth in the BDS Segment, that offset 12% decline in the Engineering Segment HVS accounted for 46% of Total Revenue driven by biologics,
Slide 6: Structurally Strong and Durable Demand Environment Today
__________ * Our Proprietary Platforms include Alina®, Aidaptus® and Deora® Structurally Strong and Durable Demand Environment Today GLP-1 revenue predominantly tied to commercial products from main originators Actively working with over 30 global GLP-1 customers for multiple programs in various sta
Slide 7: Latina and Fishers Facility Updates
Latina, Italy Commercial operations for EZ-fill® PFS running smoothly, and advancing customer audit and validations Next expansion phase dedicated to EZ-fill® cartridges, where demand for EZ-fill® cartridges remains elevated, with the market expanding beyond just the traditional cartridge players. O
Slide 8: Biologics Market Expected to Underpin FY 2027 Demand
Biologics Market Expected to Underpin FY 2027 Demand Another strong core business delivery in Q3, in line with our expectations Demand environment for injectable biologics remains strong, driven by secular tailwinds Business positioned in the most attractive areas of the market, particularly biologi
Slide 9: Marco Dal Lago, Chief Financial Officer
Marco Dal Lago Chief Financial Officer Q3 2026 Financial Results
Slide 10: Q3 2026: Financial Highlights
Q3 2026: Financial Highlights __________ All comparisons refer to Q3 2025 unless otherwise specified. *Organic Revenue and Change in organic revenue, adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA, adjusted EBITDA margin, are non-GAAP financial measures. Please
Slide 11: Q3 2026: Segment Trends
Q3 2026: Segment Trends 267† Q3 2025 294 Q3 2026 Revenue increased 10%, and 11% on an organic* basis Revenue from HVS was €149.4M, or approx. 51% of BDS Segment revenue Revenue from other containment and delivery solutions was €144.6M (increasing 22% and 23% organically), driven by growth in standar
Slide 12: Balance Sheet and Cash Flow Items
Balance Sheet and Cash Flow Items __________ *Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 16 to 22 for a reconciliation of non-GAAP measures. In the Third Quarter of 2026 Cash from operating activities + € 57.6 M Cash used in the purchase of property, plan
Slide 13: Reiterating FY26 Guidance
Reiterating FY26 Guidance __________ *Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA and adjusted EBITDA margin, Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 16 to 22 for a reconciliation of non-GAAP measures. **Implie
Slide 14: Solid Performance in Q3 2026; On Track to Achieve FY26 Objectives
Solid Performance in Q3 2026; On Track to Achieve FY26 Objectives In the short term, the adjustment in GLP revenue is exp. to temporarily moderate growth in 2027. We believe we can backfill in 2027 with growing biologics demand. Based on what we know today, believe we can grow LSD in 2027 Exp. main
Slide 15: Upcoming Conferences and Marketing Activities
Upcoming Conferences and Marketing Activities Jefferies Healthcare Conference in London – November 18, 2026 KeyBanc Investor Trip to Latina facility – November 20, 2026 Citi Global Healthcare Conference in Miami – December 2, 2026 CJS Securities Annual “New Ideas for the New Year” (virtual) – Januar
Slide 16: Non-GAAP Financial Measures Definitions
This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency
Slide 17: Reconciliation of Non-GAAP Financial Measures (1/6)
Reconciliation of Non-GAAP Financial Measures (1/6) Reconciliation of EBITDA (Amounts in € millions) Calculation of Net Profit margin, Operating Profit Margin, Adjusted EBITDA Margin and Adjusted Operating Profit Margin (Amounts in € millions) Q3 2026 Financial Results
Slide 18: Reconciliation of Non-GAAP Financial Measures (2/6)
Q3 2026 Financial Results Reconciliation of Non-GAAP Financial Measures (2/6) Reconciliation of Revenue to Organic Revenue (Amounts in € millions) (*) As no acquisition-related adjustments were required for the three and the nine months ended September 30, 2026, Constant Currency Revenue and Organic
Slide 19: Reconciliation of Non-GAAP Financial Measures (3/6)
Reconciliation of Non-GAAP Financial Measures (3/6) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) (1) During the three and the nine months ended September 30, 2026, the Group recorded EUR 2.4
Slide 20: Reconciliation of Non-GAAP Financial Measures (4/6)
Reconciliation of Non-GAAP Financial Measures (4/6) Capital Employed (Amounts in € millions) Q3 2026 Financial Results
Slide 21: Reconciliation of Non-GAAP Financial Measures (5/6)
Reconciliation of Non-GAAP Financial Measures (5/6) Net (Debt) / Net Cash (Amounts in € millions) Free Cash Flow (Amounts in € millions) CAPEX (Amounts in € millions) Q3 2026 Financial Results
Slide 22: Reconciliation of Non-GAAP Financial Measures (6/6)
Reconciliation of Non-GAAP Financial Measures (6/6) Reconciliation of 2026 Guidance(*) Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) (*) Amounts may not add due to rounding Q3 2026 Financial Results